**Agenda PINTAD**


Feb 24th, 2017, 11am EST

1. **Welcome**
2. Follow-up on the founding of an imaging-specific CDISC User Group initially under the PINTAD umbrella (for expressions of interest please contact [daniel.clark@PAREXEL.com](mailto:daniel.clark@PAREXEL.com))
   * *Only one response so far- is there no interest?*
   * *Dan Clark to create a brief statement to share with PINTAD to garner further support. It was suggested to target specifically data managers and programming team members- however this should be an important topic for all of us.*
3. Further update on user stories/ Software Standards for Extending the PACS Environment/ DICOM Part 19
   * *Developing “User Stories” around the topical areas of Companion Diagnostics and Clinical Trials for likely discussion within WG-23. Misha will continue to solicit inputs from those within PINTAD that showed an interest following the Oct 28th presentation.*
   * *Larry Tarbox mentioned that DICOM WG-23 (Application Hosting) has reconvened, and will be considering proposals for improving the existing application hosting, and for a new generation of APIs based on RESTful web services.  They are accepting user stories as we speak.*
   * *He encouraged PINTAD members to join the observer list or become active members if interested. He will create a brief statement to share with the group that includes info on how to join.*
4. Update on Value Proposition of Imaging PINTAD subgroup

* Brian Garra FDA/ VA, Kim Leigh/ Amgen and Peter Steiger/PAREXEL, Susanta Sarkar/ Cadenzamed leading the effort
* *Brian Garra and Susanta Sarkar mentioned that the group has been collecting information and details on the value of imaging in clinical trials and are now shaping the content of a potential PINTAD statement.*
* *Susanta Sarkar to circle back to the group and let us know when they are ready for an update*

1. Update on the final push for a consensus on Incidental Findings Reporting
   * *12 in support of both portions*
   * *1 in support of Part I but not Part II*
   * *2 voted against both parts*
   * *Can we work towards more responses?*
   * *Brian Garra suggested to circulate a red-lined document to give people a better sense of what has been changed from the prior version*
   * *Annette Schmid to reach out to individuals and the group to encourage more voting. We need to have at least 1/3 of the members on the distribution list respond to have credibility.*
2. Update on the support of the QIBA value proposition (Moonshot)
   * *26 signatories from a range of pharma, hospitals, Imaging Core Labs and consultants- THANK YOU!*
   * *Two of the QIBA Profiles relevant to cancer patients have been referenced and supported by the Federal Cancer Moonshot Initiative (*[*https://medium.com/cancer-moonshot/standards-for-quantitative-imaging-biomarkers-to-advance-research-and-outcomes-in-the-cancer-6e4e4ebf4e75#.n16js0mg1*](https://medium.com/cancer-moonshot/standards-for-quantitative-imaging-biomarkers-to-advance-research-and-outcomes-in-the-cancer-6e4e4ebf4e75#.n16js0mg1)*) and* [*http://www.rsna.org/news.aspx?id=21083*](http://www.rsna.org/news.aspx?id=21083)
   * *Annette Schmid mentioned how important this is to the visibility of QIBA and the QIBA profiles.*
   * *Dan Sullivan added his thank you for the support from the PINTAD members. He is receiving the statistics on how frequently the report is opened and presumable read, which occurred > 1000x.*
3. Ad- hoc topics:

* Language improvement of our Mission Statement/ Definition Section as suggested by Paul Garrett
  + *shouldn't it read "While* ***members of the****pharmacologic, biotechnology, and medical device* ***industries****, etc..... Perhaps individuals such as "academicians and consultants" as well as clinicians and radiologists could be specified in a separate sentence for precise grammar.*



* *Those on the phone accepted and welcomed the change. Annette Schmid to implement and highlight in the next mailings to the group.*
* Next month’s topic: Greg Goldmacher will provide an update on immune related criteria for solid tumors

1. Reminder to submit questions that would benefit from FDA feedback